Jim Cramer
Here’s why Jim Cramer says investors should stay away from ‘fool’s gold’ software stocks
CNBC’s Jim Cramer on Wednesday advised investors to stay away from software stocks. “Data has become fool’s gold. Data is iron pyrite. When you hear the word data and you see a loss, I don’t care what kind of growth the company has, I don’t care what kind of software it owns, it is bad,” […]
Read More
We still see Estee Lauder shares as a buy on weakness despite downbeat guidance
Estee Lauder (EL) reported a better-than-expected fiscal first quarter, but a downbeat forecast for the rest of its fiscal year sent shares lower Wednesday. However, if not for our Club trading restrictions , we would have been buyers on the weakness. First, the headline numbers: Quarterly revenue declined 11% year over year to $3.93 billion, […]
Read More
We’re impressed with health insurer Humana’s solid quarter and rosy outlook for next year
Club holding Humana (HUM) reported a mixed-but-solid third quarter before the opening bell Wednesday. Early optimism about 2023 also supported our bullish view on the health insurer’s stock. Revenue increased 9% year-over-year to $22.75 billion, slightly below estimates of $22.76 billion, and adjusted earnings-per-share increased 42% to $6.88, exceeding estimates of $6.28 per share. Aiding […]
Read More
Eli Lilly’s guidance cut is about the strong dollar, not weakening fundamentals, CEO says
Eli Lilly (LLY) CEO David Ricks on Tuesday expressed optimism around the drugmaker’s innovation pipeline Tuesday, a stance we share despite the Club holding’s cluttered quarterly report issued earlier in the day . “The underlying fundamentals of the business are really strong,” Ricks said in a CNBC interview with Jim Cramer. “Seventy percent of our […]
Read More
Jim Cramer says these 8 stocks can withstand the Fed’s tightening cycle
CNBC’s Jim Cramer on Tuesday offered investors a list of stocks that he thinks will weather the market turbulence ahead. Here are his picks: Constellation Brands Eli Lilly Mondelez Kraft Kellogg Colgate Procter & Gamble Johnson & Johnson “You have to go to the new leaders of this market. Leaders like health care, leaders like […]
Read More
Cramer’s lightning round: Manulife is not a buy
Tellurian Inc: “I am still in the buy, buy, buy. … It’s early in the game.” Planet Labs PBC: “It’s a really interesting concept. Sometimes you can own a concept. That’s a concept.” Jim Cramer’s Guide to Investing Click here to download Jim Cramer’s Guide to Investing at no cost to help you build long-term wealth and […]
Read More
Our guide to semiconductor companies and how their chips run our everyday lives
The semiconductor, or chip, industry is perhaps one of the most important and complex sectors in the stock market to understand. Chips are in everything from our smartphones to cars and to all facets of computing, from PCs to massive data centers used for the cloud. Put simply, they are the bricks and mortar of […]
Read More
J&J’s nearly $17 billion offer to buy a heart pump maker goes right to why we own it
Johnson & Johnson ‘s (JNJ) $16.6 billion deal to buy heart pump maker Abiomed (ABMD) will bolster its pharmaceutical and medical device business ahead of J & J’s plans to separate its consumer division into a separate company. The Abiomed acquisition is set to close at the end of the first quarter of 2023. The […]
Read More
‘Hold your nose and sell’ to brace for a possible market downturn, Jim Cramer says
CNBC’s Jim Cramer on Monday warned investors that they should trim some of their positions to prepare for a possible market decline. “According to the S&P oscillator I’ve followed for ages, we’re very overbought right now,” he said. “You have to hold your nose and sell something because we’re due for a pullback.” The S&P […]
Read More
Cramer’s lightning round: Riot Blockchain is not a buy
Palantir: “If it can get to $10, then I would skedaddle. I hate to recommend it all the way down here because it’s near the bottom.” Black Knight Inc: “The government is so fickle, I hesitate to recommend any arbitrage situation.” Match Group Inc: “At $43? Really? I’m not going to recommend a sale of […]
Read More